{"id":16058,"date":"2025-04-13T08:47:07","date_gmt":"2025-04-13T08:47:07","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/16058\/"},"modified":"2025-04-13T08:47:07","modified_gmt":"2025-04-13T08:47:07","slug":"one-study-explored-the-effects-of-mounjaro-over-several-years","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/16058\/","title":{"rendered":"One Study Explored the Effects of Mounjaro Over Several Years"},"content":{"rendered":"<p>We\u2019re currently living through a moment in time when GLP-1 medications like Ozempic and Mounjaro are transforming our expectations about diabetes, weight loss and fitness. But there\u2019s another large question looming overhead when it comes to these medications: can they sustain weight loss in the long term? While it isn\u2019t quite an existential question for the health care industry, it has prompted some pushback from <a href=\"https:\/\/www.insidehook.com\/television\/bill-maher-real-time-jillian-michaels-ozempic\" target=\"_blank\" rel=\"noopener\">skeptics<\/a> of the drugs\u2019 long-term safety. <\/p>\n<p>According to a new study, people taking Mounjaro (aka tirzepatide) have some cause for relief. The Guardian\u2018s Nicola Davis recently <a href=\"https:\/\/www.theguardian.com\/society\/2025\/apr\/11\/people-using-drug-mounjaro-sustain-weight-loss-over-three-years-trial-finds\" target=\"_blank\" rel=\"noopener\">reported<\/a> on the results of a study that is set to be presented at this year\u2019s <a href=\"https:\/\/easo.org\/congress\/\" target=\"_blank\" rel=\"noopener\">European Congress on Obesity<\/a>. The study encompassed around 700 people, who were divided into three groups based on the amount of tirzepatide that they were given.<\/p>\n<p>Among the researchers\u2019 findings, Davis writes, were that participants in the groups lost, on average, 9.2%, 20.2% and 30.8% of their body weight, depending on which group they were in. The scientists conducting the study observed that participants took an average of 22 months to reach their lowest weight. And the majority of participants lost almost 20% of their starting weight over the course of three years.<\/p>\n<p>\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/www.insidehook.com\/fitness\/brain-mice-human-appetites-science-study\" class=\"align-middle\" target=\"_blank\" rel=\"noopener\"><br \/>\n\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/04\/place-setting.jpg\" alt=\"Mouse Brains Could Help Us Better Understand Human Appetites\" loading=\"lazy\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>There are some caveats here: for starters, The Guardian\u2018s reporting notes that the study was not peer reviewed. But these results are nonetheless encouraging for people concerned about the long-term effects of this medication \u2014 and whether promising initial results can be sustained over time.<\/p>\n<p>\t\t\t\t\t\t\tMore Like This<\/p>\n<p><b data-stringify-type=\"bold\">Whether you\u2019re looking to get into shape, or just get out of a funk,\u00a0<\/b><b data-stringify-type=\"bold\"><a class=\"c-link\" href=\"https:\/\/www.insidehook.com\/campaign\/the-charge?eid=%7B%7Bmd5(email)%7D%7D&amp;lctg=%7B%7Bprofile.id%7D%7D&amp;utm_source=InsideHook&amp;utm_medium=text-module\" target=\"_blank\" rel=\"noopener noreferrer\" data-stringify-link=\"https:\/\/www.insidehook.com\/campaign\/the-charge?eid=%7B%7Bmd5(email)%7D%7D&amp;lctg=%7B%7Bprofile.id%7D%7D&amp;utm_source=InsideHook&amp;utm_medium=email\" data-sk=\"tooltip_parent\">The Charge<\/a><\/b><b data-stringify-type=\"bold\">\u00a0has got\u00a0<\/b><b data-stringify-type=\"bold\">you<\/b><b data-stringify-type=\"bold\">\u00a0covered. Sign up for our new wellness newsletter today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"We\u2019re currently living through a moment in time when GLP-1 medications like Ozempic and Mounjaro are transforming our&hellip;\n","protected":false},"author":2,"featured_media":16059,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[10893,3907,1630,105,4326,370,16,15,10891,10892,2488],"class_list":{"0":"post-16058","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-0-249-words","9":"tag-article","10":"tag-fitness","11":"tag-health","12":"tag-medication","13":"tag-ozempic","14":"tag-uk","15":"tag-united-kingdom","16":"tag-wegovy","17":"tag-weightloss","18":"tag-wellness"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114329789621405021","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/16058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=16058"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/16058\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/16059"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=16058"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=16058"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=16058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}